Previous 10 | Next 10 |
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Ma...
2023-03-09 12:05:21 ET Harvard Bioscience, Inc. (HBIO) Q4 2022 Earnings Call Transcript March 09, 2023 08:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting Jim Green - Chairman of the Board, President & Chief Executive...
2023-03-09 10:06:39 ET The following slide deck was published by Harvard Bioscience, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Harvard Bioscience, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-09 07:15:05 ET Harvard Bioscience press release ( NASDAQ: HBIO ): Q4 Non-GAAP EPS of $0.04 beats by $0.03 . Revenue of $28.4M (-14.2% Y/Y) misses by $1.75M . Jim Green, Chairman and CEO, concluded, “Looking to the future, I am excited about our p...
HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparabl...
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. ...
Summary Bruker offers a range of advantages over peers: profitability, value, growth, and more. As such, the company is well-positioned to provide strong returns in the future. This article will address recent developments, highlight the advantages, and discuss the opportunity. ...
Harvard Bioscience ( NASDAQ: HBIO ) announced the resignation of Michael Rossi, the company’s CFO and treasurer, effective December 31, 2022. The company has appointed Jennifer Cote, the company’s VP of global finance, as its interim CFO and treasurer, effective...
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer C...
The following slide deck was published by Harvard Bioscience, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Harvard Bioscience, Inc. 2022 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Harvard Bioscience Inc. Company Name:
HBIO Stock Symbol:
NASDAQ Market:
Harvard Bioscience Inc. Website:
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14 th Annual East Coast IDEAS Conference at the ...
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriot...
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22 ...